Incyclix Bio, LLC, a cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the ...
Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced ...
Research into cell cycle regulation and size control in microorganisms has yielded a nuanced understanding of how these entities maintain homeostasis and synchronise growth with division. In both ...
Arteriovenous malformations, a hallmark of hereditary hemorrhagic telangiectasia, may be driven by endothelial cell-cycle acceleration via CDK6, suggesting potential for repurposing CDK6 inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results